» Articles » PMID: 30808235

Five Years of Successful Inducible Transgene Expression Following Locoregional Adeno-Associated Virus Delivery in Nonhuman Primates with No Detectable Immunity

Overview
Journal Hum Gene Ther
Specialties Genetics
Pharmacology
Date 2019 Feb 28
PMID 30808235
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Anti-transgene immune responses elicited after intramuscular (i.m.) delivery of recombinant adeno-associated virus (rAAV) have been shown to hamper long-term transgene expression in large-animal models of rAAV-mediated gene transfer. To overcome this hurdle, an alternative mode of delivery of rAAV vectors in nonhuman primate muscles has been described: the locoregional (LR) intravenous route of administration. Using this injection mode, persistent inducible transgene expression for at least 1 year under the control of the tetracycline-inducible Tet-On system was previously reported in cynomolgus monkeys, with no immunity against the rtTA transgene product. The present study shows the long-term follow-up of these animals. It is reported that LR delivery of a rAAV2/1 vector allows long-term inducible expression up to at least 5 years post gene transfer, with no any detectable host immune response against the transactivator rtTA, despite its immunogenicity following i.m. gene transfer. This study shows for the first time a long-term regulation of muscle gene expression using a Tet-On-inducible system in a large-animal model. Moreover, these findings further confirm that the rAAV LR delivery route is efficient and immunologically safe, allowing long-term skeletal muscle gene transfer.

Citing Articles

Gene Therapy in the Light of Lifestyle Diseases: Budesonide, Acetaminophen and Simvastatin Modulates rAAV Transduction Efficiency.

Slyk Z, Stachowiak N, Malecki M Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338375 PMC: 11434873. DOI: 10.3390/ph17091213.


Limb Perfusion Delivery of a rAAV1 Alpha-1 Antitrypsin Vector in Non-Human Primates Is Safe but Insufficient for Therapy.

Pires-Ferreira D, Reil D, Tang Q, Blackwood M, Gallagher T, Keeler A Genes (Basel). 2024; 15(9).

PMID: 39336779 PMC: 11431094. DOI: 10.3390/genes15091188.


AAV-NRIP gene therapy ameliorates motor neuron degeneration and muscle atrophy in ALS model mice.

Chen H, Yeo H, Huang Y, Tsai L, Lai H, Tsao Y Skelet Muscle. 2024; 14(1):17.

PMID: 39044305 PMC: 11267858. DOI: 10.1186/s13395-024-00349-z.


Gene therapy for neurotransmitter-related disorders.

Chu W, Ng J, Waddington S, Kurian M J Inherit Metab Dis. 2024; 47(1):176-191.

PMID: 38221762 PMC: 11108624. DOI: 10.1002/jimd.12697.


Transcriptomic Analysis Reveals the Inability of Recombinant AAV8 to Activate Human Monocyte-Derived Dendritic Cells.

Masri S, Carre L, Jaulin N, Vandamme C, Couzinie C, Guy-Duche A Int J Mol Sci. 2023; 24(13).

PMID: 37445621 PMC: 10341499. DOI: 10.3390/ijms241310447.


References
1.
Lee Y, Conlon T, Specht A, Coleman K, Brown L, Estrella A . Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia. J Inherit Metab Dis. 2018; 41(6):977-984. DOI: 10.1007/s10545-018-0199-7. View

2.
Jiang H, Pierce G, Ozelo M, de Paula E, Vargas J, Smith P . Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther. 2006; 14(3):452-5. DOI: 10.1016/j.ymthe.2006.05.004. View

3.
Le Guiner C, Servais L, Montus M, Larcher T, Fraysse B, Moullec S . Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat Commun. 2017; 8:16105. PMC: 5537486. DOI: 10.1038/ncomms16105. View

4.
Nathwani A, Rosales C, McIntosh J, Rastegarlari G, Nathwani D, Raj D . Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther. 2011; 19(5):876-85. PMC: 3098629. DOI: 10.1038/mt.2010.274. View

5.
Gernoux G, Wilson J, Mueller C . Regulatory and Exhausted T Cell Responses to AAV Capsid. Hum Gene Ther. 2017; 28(4):338-349. PMC: 5399736. DOI: 10.1089/hum.2017.022. View